A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma
Nway Le Ko Ko, Nareg Minaskeian, Hicham Z. El Masry
Cardio-Oncology · 2020
doi:10.1186/s40959-020-00077-5 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Abstract This is a case of a middle-aged woman with underlying cardiac conduction system with episodes of AV Wenckebach, who subsequently developed significant AV conduction system abnormalities after receiving one standard dose of Rituximab infusion for diffuse large B-cell lymphoma. Rituximab, being a monoclonal antibody against CD-20 antigen, is effective in treatment of B-cell lymphoma but may also cause bradyarrythmias likely due to the calcium ion channel property of CD-20 antigen.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.